Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CLDN6/CD3 BiTE antibody AMG 794

A half-life extended (HLE) human bispecific T-cell engager (BiTE) antibody targeting the CD3 antigen expressed on T lymphocytes and the cell surface protein claudin 6 (CLDN6; CLDN-6), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CLDN6/CD3 BiTE antibody AMG 794 targets and binds to both CD3 expressed on T cells and CLDN6 expressed on tumor cells. This activates and redirects cytotoxic T lymphocytes (CTLs) to CLDN6-expressing tumor cells, produces cytokines and leads to enhanced CTL-mediated elimination of CLDN6-expressing tumor cells. CLDN6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CLDN6/CD3 bispecific T-cell engager AMG 794
CLDN6xCD3 bispecific T-cell engager AMG 794
Code name:AMG 794
AMG-794
AMG794
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search